Loading...
XLONSN.
Market cap10bUSD
Mar 24, Last price  
1,239.16GBP
Name

Smith & Nephew PLC

Chart & Performance

D1W1MN
XLON:SN. chart
P/E
5,150.12
P/S
244.09
EPS
0.30
Div Yield, %
0.03%
Shrs. gr., 5y
-13.00%
Rev. gr., 5y
2.50%
Revenues
5.55b
+6.40%
2,394,698,4802,552,000,0002,779,000,0003,369,000,0003,801,000,0003,772,000,0003,962,000,0004,270,000,0004,137,000,0004,351,000,0004,617,000,0004,634,000,0004,669,000,0004,765,000,0004,904,000,0005,138,000,0004,560,000,0005,212,000,0005,215,000,0005,549,000,000
Net income
263m
+17.94%
290,010,741333,000,000745,000,000316,000,000377,000,000472,000,000615,000,000582,000,000729,000,000556,000,000501,000,000410,000,000784,000,000767,000,000663,000,000600,000,000448,000,000524,000,000223,000,000263,000,000
CFO
608m
+29.91%
363,280,650260,000,000352,000,000424,000,000566,000,000719,000,000859,000,000842,000,000902,000,000867,000,000683,000,0001,030,000,000849,000,0001,090,000,000931,000,0001,168,000,000935,000,000877,000,000468,000,000608,000,000
Dividend
Apr 02, 20200.1866 GBP/sh
Earnings
Feb 25, 2025

Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
IPO date
Aug 13, 1951
Employees
19,000
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,549,000
6.40%
5,215,000
0.06%
5,212,000
14.30%
Cost of revenue
4,631,000
6,908,000
6,644,000
Unusual Expense (Income)
NOPBT
918,000
(1,693,000)
(1,432,000)
NOPBT Margin
16.54%
Operating Taxes
27,000
12,000
62,000
Tax Rate
2.94%
NOPAT
891,000
(1,705,000)
(1,494,000)
Net income
263,000
17.94%
223,000
-57.44%
524,000
16.96%
Dividends
(327,000)
(327,000)
(329,000)
Dividend yield
5.79%
Proceeds from repurchase of equity
(152,000)
59,000
BB yield
-1.04%
Debt
Debt current
765,000
160,000
491,000
Long-term debt
2,518,000
2,712,000
2,848,000
Deferred revenue
2,529,000
2,563,000
Other long-term liabilities
171,000
(2,565,000)
(2,707,000)
Net debt
2,957,000
2,464,000
1,851,000
Cash flow
Cash from operating activities
608,000
468,000
877,000
CAPEX
(427,000)
(358,000)
(408,000)
Cash from investing activities
(448,000)
(472,000)
(691,000)
Cash from financing activities
(200,000)
(926,000)
(645,000)
FCF
387,000
(2,104,000)
(1,501,000)
Balance
Cash
302,000
350,000
1,290,000
Long term investments
24,000
58,000
198,000
Excess cash
48,550
147,250
1,227,400
Stockholders' equity
4,696,000
5,201,000
5,402,000
Invested Capital
8,423,450
8,013,750
7,686,600
ROIC
10.84%
ROCE
10.82%
EV
Common stock shares outstanding
436,877
436,500
439,000
Price
12.94
-14.34%
Market cap
5,678,465
-14.24%
EV
7,857,465
EBITDA
1,445,000
(1,188,000)
(910,000)
EV/EBITDA
Interest
139,000
80,000
80,000
Interest/NOPBT
15.14%